Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed-cisplatin chemotherapy with or without necitumumab in first-line stage IV nonsquamous NSCLC
2009-012574-12Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of necitumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall survival. Started Aug 2009; status: completed.
02
Drugs
necitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-012574-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012574-12.